A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts).Shubham Pant, Manish R. Patel, Dan Wang et al.|Journal of Clinical Oncology|2019Cited by 24
First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and PharmacodynamicsAshish Bajel, Anthony S. Stein, Sylvain Garciaz et al.|Blood|2023Cited by 24
A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia.Anthony S. Stein, Ashish Bajel, Mojca Jongen‐Lavrencic et al.|Journal of Clinical Oncology|2023Cited by 12
P494: A FIRST-IN-HUMAN STUDY OF CD123 NK CELL ENGAGER SAR443579 IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA OR HIGH RISK-MYELODYSPLASIAAnthony S. Stein, Ashish Bajel, Mojca Jongen‐Lavrencic et al.|HemaSphere|2023Cited by 2